Literature DB >> 11710544

Differential activities of decapeptide agonists of human C5a: the conformational effects of backbone N-methylation.

S M Vogen1, N J Paczkowski, L Kirnarsky, A Short, J B Whitmore, S A Sherman, S M Taylor, S D Sanderson.   

Abstract

Analogues of the potent, conformationally biased, decapeptide agonist of human C5a anaphylatoxin, C5a(65-74)Y65,F67,P69,P71,D-Ala73 (YSFKPMPLaR, peptide 54), were synthesized with methyl groups occupying specific amide nitrogen atoms along the peptide backbone. This N-methylation induced crucial extended backbone conformations in a manner similar to the two Pro residues, but without eliminating the contributions made by the side-chain of the residue for which Pro was substituted. The presence of backbone N-methyl groups on peptide 54 analogues had pronounced detrimental effects on the ability to bind and activate C5aRs expressed on human PMNs, but not on the ability to contract smooth muscle of human umbilical artery. Several N-methylated analogues of peptide 54 (peptides 56, 67, 124, 125, and 137) were significantly more selective for smooth muscle contraction, which is mediated by tissue resident macrophages, than for enzyme release from PMNs. Indeed, peptide 67, YSFKDMP(MeL)aR was almost 3000-fold more selective for smooth muscle contraction than for PMN enzyme release. Consistent with these differential activities was the observation that peptide 67 expressed a significantly greater binding affinity to C5aRs expressed on rat macrophages than on rat PMNs. This differential activity was also observed in vivo in the rat where peptide 67 induced a hypotensive response similar to peptide 54 and rhuC5a, but without accompanying neutropenia.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11710544     DOI: 10.1016/s1567-5769(01)00141-2

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  13 in total

1.  Surface conjugation of EP67 to biodegradable nanoparticles increases the generation of long-lived mucosal and systemic memory T-cells by encapsulated protein vaccine after respiratory immunization and subsequent T-cell-mediated protection against respiratory infection.

Authors:  Shailendra B Tallapaka; Bala V K Karuturi; Pravin Yeapuri; Stephen M Curran; Yogesh A Sonawane; Joy A Phillips; D David Smith; Sam D Sanderson; Joseph A Vetro
Journal:  Int J Pharm       Date:  2019-05-08       Impact factor: 5.875

2.  Encapsulation of an EP67-Conjugated CTL Peptide Vaccine in Nanoscale Biodegradable Particles Increases the Efficacy of Respiratory Immunization and Affects the Magnitude and Memory Subsets of Vaccine-Generated Mucosal and Systemic CD8+ T Cells in a Diameter-Dependent Manner.

Authors:  Bala V K Karuturi; Shailendra B Tallapaka; Pravin Yeapuri; Stephen M Curran; Sam D Sanderson; Joseph A Vetro
Journal:  Mol Pharm       Date:  2017-04-03       Impact factor: 4.939

3.  Control of methicillin resistant Staphylococcus aureus infection utilizing a novel immunostimulatory peptide.

Authors:  Tamsin R Sheen; Courtney K Cavaco; Celia M Ebrahimi; Marilyn L Thoman; Sam D Sanderson; Edward L Morgan; Kelly S Doran
Journal:  Vaccine       Date:  2011-10-30       Impact factor: 3.641

4.  Preliminary evidence that the novel host-derived immunostimulant EP67 can act as a mucosal adjuvant.

Authors:  Bala Vamsi K Karuturi; Shailendra B Tallapaka; Joy A Phillips; Sam D Sanderson; Joseph A Vetro
Journal:  Clin Immunol       Date:  2015-06-23       Impact factor: 3.969

5.  Progress Toward a Human Vaccine Against Coccidioidomycosis.

Authors:  Garry T Cole; Brady J Hurtgen; Chiung-Yu Hung
Journal:  Curr Fungal Infect Rep       Date:  2012-12-01

6.  Enhancement of in vivo and in vitro immune functions by a conformationally biased, response-selective agonist of human C5a: implications for a novel adjuvant in vaccine design.

Authors:  Edward L Morgan; Brandon N Morgan; Elisabeth A Stein; Elizabeth L Vitrs; Marilyn L Thoman; Sam D Sanderson; Joy A Phillips
Journal:  Vaccine       Date:  2009-10-15       Impact factor: 3.641

7.  Single-step conjugation of bioactive peptides to proteins via a self-contained succinimidyl bis-arylhydrazone.

Authors:  Joy A Phillips; Edward L Morgan; Yuxiang Dong; Garry T Cole; Cody McMahan; Chiung-Yu Hung; Sam D Sanderson
Journal:  Bioconjug Chem       Date:  2009-09-29       Impact factor: 4.774

8.  Targeted Amino Acid Substitution Overcomes Scale-Up Challenges with the Human C5a-Derived Decapeptide Immunostimulant EP67.

Authors:  Abdulraman M Alshammari; D David Smith; Jake Parriott; Jason P Stewart; Stephen M Curran; Russell J McCulloh; Peter A Barry; Smita S Iyer; Nicholas Palermo; Joy A Phillips; Yuxiang Dong; Donald R Ronning; Jonathan L Vennerstrom; Sam D Sanderson; Joseph A Vetro
Journal:  ACS Infect Dis       Date:  2020-04-13       Impact factor: 5.084

9.  An agonist of human complement fragment C5a enhances vaccine immunity against Coccidioides infection.

Authors:  Chiung-Yu Hung; Brady J Hurtgen; Michael Bellecourt; Sam D Sanderson; Edward L Morgan; Garry T Cole
Journal:  Vaccine       Date:  2012-05-08       Impact factor: 3.641

10.  A novel C5a-derived immunobiotic peptide reduces Streptococcus agalactiae colonization through targeted bacterial killing.

Authors:  Courtney K Cavaco; Kathryn A Patras; Jaime E Zlamal; Marilyn L Thoman; Edward L Morgan; Sam D Sanderson; Kelly S Doran
Journal:  Antimicrob Agents Chemother       Date:  2013-08-26       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.